Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

Detailed price information for Springworks Therapeutics Inc (SWTX-Q) from The Globe and Mail including charting and trades.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition ...

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue ...

Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds.

SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “neutral” rating restated by equities research analysts at Guggenheim in a research note issued to investors on ...

Stifel Financial Corp reduced its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 7.7% in the 4th quarter, according to the company in its most recent 13F ...

SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -37.04% and 23.53%, respectively, for the quarter ended March 2025.